Abstract:Background The concept of Mixed Connective Tissue Disease (MCTD) was first proposed by Sharp and his colleagues in 1972.1 MCTD has overlapping features between at least two autoimmune diseases, such as SLE, SSc, PM/DM and RA. Regulatory T cells (Treg cells) play a critical role in the maintenance of immune tolerance and the regulation of immune responses. Treg cell dysfunction contributes to the initiation of pathogenesis and the maintenance of high disease activity in RA and SLE.2 Recently, some studies have indicated that the proportion of Treg cells was different from healthy controls in SSc patients.3 Therefore, MCTD may be associated with Treg cells. Objectives To explore the status of CD4+T cells in peripheral blood of patients with MCTD; to explore the effect of low dose interleukin -2 (IL-2) treatment on the balance of Treg cells and Th17 cells in patients with MCTD, and to observe the short-term curative effect. Methods CD4+T cells in the peripheral blood of 58 MCTD patients and 33 healthy controls were analyzed by flow cytometry. All of 58 cases were treated with standard therapy, including corticosteroids, NSAIDs, immunosuppressants, or combination therapy. Among them, 26 cases of MCTD without using immunosuppressant (CYC, MTX, LEF, MMF), were as untreated group, another 32 cases were as treated group. Then we compared the difference of CD4+T cells between two groups. In 58 patients with MCTD, a total of 27 patients were treated with low-dose IL-2 (50WIU) on the basis of standard treatment for 5 days. The difference of CD4+T cells before and after treatment with IL-2 was compared. Results The absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD was significantly lower than those in healthy controls. There was no significant difference in the absolute count of CD4+CD25+FOXP3+Treg cells in the peripheral blood between the treated group and the untreated group. The absolute count of CD4+CD25+FOXP3+Treg cells was significantly higher than those before treatment with IL-2. Conclusions The absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD were significantly reduced, which may be the mechanism of immune imbalance in MCTD patients. The decrease of the absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD was not associated with the use of immunosuppressive agents. Low dose and short-term IL-2 treatment may increase the absolute count of CD4+CD25+FOXP3+Treg cells in the peripheral blood in patients with MCTD, so as to restore the immune balance in patients with MCTD. References Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specifi c antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148–159. Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol, 2009, 16(4):274–279. Cordiali-Fei P, Mussi A, D9Agosto G, et al. Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol, 2013, 2013:390563. Acknowledgements Thanks to my supervisor, my colleagues and superiors. Disclosure of Interest None declared

Finite Geometry and Combinatorics: Group-arcs of prime power order on cubic curves

Case report: Primary immunodeficiency due to a novel mutation in CARMIL2 and its response to combined immunomodulatory therapy

AB0612 Efficacy of Low Dose and Short-Term IL-2 Treatment to Expand Endogenous Regulatory T Cells in Patients with Mixed Connective Tissue Disease

Light-dark cues entrain oviposition time in the chicken hen

A human immunodeficiency syndrome caused by mutations in CARMIL2

Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study

IL-2 enhances effector function but suppresses follicular localization of CD8 T cells in chronic infection

CARMIL2 Deficiency Presenting as Very Early Onset Inflammatory Bowel Disease

Activation and long-term proliferation of human cord blood T cells with human recombinant interleukin-2

Proximity-enabled Covalent Binding of IL-2 to IL-2Rα Selectively Activates Regulatory T Cells and Suppresses Autoimmunity.

The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial

Interleukin-2 and regulatory T cells in rheumatic diseases

Novel CARMIL2 loss-of-function variants are associated with pediatric inflammatory bowel disease

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

Partial T cell defects and expanded CD56bright NK cells in an SCID patient carrying hypomorphic mutation in the IL2RG gene

Blocking common γ chain cytokine signaling ameliorates T cell–mediated pathogenesis in disease models

Human interleukin-2 receptor β mutations associated with defects in immunity and peripheral tolerance

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

Abstract 4062: A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 capable of delivering IL2 to LAG3+ cells while remaining inert on LAG3- cells

Abstract A029: Preferential ability of IL-7 versus IL-2 to restore effector T cell responses in the presence of regulatory T cells assessed using MR-MCTM assays in vitro

Human Orthogonal IL-2/IL-2Rβ As a Tunable Approach to Enhance CD19-Speific CAR-T Cell Antitumor Activity